- Fee assured
- Awaiting verification
This healthcare professional let us know that they are currently:
- Accepting new patients
- Available for:
- Phone consultations
- Face-to-face consultations
- Video consultations
Last updated: 12 May 2020
Dr Colaco is a consultant clinical oncologist with a specialist interest in proton therapy,stereotactic radiotherapy and adult primary brain tumours. He also specialises in stereotactic radiotherapy for brain metastases and oligo-metastatic cancers.
After completing his training as a specialist registrar in Clinical Oncology at the Christie, Dr Colaco was selected as the first UK doctor to train in proton therapy spending 12 months working in proton therapy at the University of Florida Proton Therapy Institute in Jacksonville, Florida.
He was subsequently the first graduate of the Stereotactic Radiosurgery and Radiotherapy program at Yale University in Connecticut, USA, where he worked with a variety of radiotherapy delivery platforms including the Cyberknife, Gammaknife and Novalis TX treating patients with stereotactic radiosurgery(SRS) for brain metastases and stereotactic ablative radiotherapy (SABR) for both primary lung tumours and oligo-metastatic disease from other primary cancer sites.
Following his return from the United States, he was appointed as a consultant clinical oncologist at The Christie where he specialises in the treatment of adult brain tumours and paediatric tumours along with stereotactic radiotherapy for brain metastases and oligo-metastases.
He also sees patients for proton therapy and is involved in the development of The Christie proton beam centre and in the Christie program for oligo-metastatic disease including treating tumours which have metastasised to bone, spine and lymph nodes with SABR.
Proton therapy, stereotactic radiotherapy, CNS tumours – Dr Colaco has presented at international conferences and published several papers on the use of proton therapy and stereotactic radiotherapy for a variety of cancer sites. He is the principal investigator at the Christie for the CORE trial which is examining the role of stereotactic radiotherapy in oligo-metastatic breast, lung and prostate cancers
Areas of interest
Stereotactic radiosurgery; brain metastasis; primary brain tumours; oligometastatic disease; bone metastasis; stereotactic radiotherapy; proton therapy
Reference number 6026485